BioMarin Pharma (BMRN) – Insiders' Blog
-
Biotechs Continue to Underperform (IBB)
-
Wall Street Looks to Soothe Biotech's Holiday Meltdown (GILD) (CELG) (AMGN)
-
BioMarin (BMRN) May Draw Interest Following Recent FDA Panel Vote (PFE) (RHHBY)
-
BioMarin (BMRN) Active; Vimizim Docs Posted Ahead of Nov. 19th FDA Panel
-
BioMarin Pharma (BMRN) Pipeline, Potential Make it Worth Another Look - Cramer
-
Alexion (ALXN), BioMarin (BMRN) Could Offer Treatment for Sick Portfolio - Cramer
-
UPDATE: BioMarin (BMRN) Won't Sell Even for 25% - 30% Premium
-
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
-
Baird Said a Genzyme (GENZ) Takeover Of BioMarin (BMRN) Makes Sense To Them
-
Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
-
Following Steven Cohen: Century Aluminum (CENX) May Be Headed to $75
-
Summary of Loeb's Third Point LLC 13F: New Stake AK Steel (AKS), Boosts Clear Channel (CCU), Cuts Dillard's (DDS)
-
BioMarin Pharmaceutical (BMRN) Hits New All-Time High
-
BioMarin Pharmaceutical (BMRN) Surges to a New All-Time High on Kuvan Approval
Back to BMRN Stock Lookup